Convergys Capital is a private venture capital firm whose owners are also owners of the UK's largest pharmaceutical suppliers with 25 years of experience in drug development and distribution.


UCLB is the commercialisation company of UCL and its associated NHS Trusts hospitals. UCLB has a long and successful track record of commercialising groundbreaking immunotherapy and gene therapy programs arising from UCL.


The UCL Technology Fund is dedicated to investing in intellectual property commercialisation opportunities arising from UCL’s world-class research base, focusing in particular on physical and life sciences. The fund is managed by AlbionVC in collaboration with UCLB.

More in this section

Our history

Headquartered in London, UK, NovalGen was formed in 2019. The company is based on proprietary innovations from UCL, London UK.

Read more

Our values

NovalGen is guided by our core set of values. The culture of NovalGen reflects these values and they help guide our decisions.

Read more